Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1/2 7Phase 1 6Phase 3 3Phase NA 1Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 5aldesleukin 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Immune Checkpoint Inhibitors 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1pembrolizumab 1pasireotide 1encorafenib 1dabrafenib 1binimetinib 1Vindesine 1Standard of Care 1Specimen Handling 1Sevoflurane 1Propofol 1Pharmaceutical Preparations 1Patient-Specific Modeling 1Isoflurane 1Interleukins 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fibrin Tissue Adhesive 1Etanercept 1Desflurane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Melanoma × sargramostim × Clear all
NCT02451488 2020-02-10

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

Mayo Clinic

Phase 4 Completed
8 enrolled 5 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡